Exploring the minimal functional unit of the transporter associated with antigen processing  by Koch, Joachim et al.
FEBS 29795 FEBS Letters 579 (2005) 4413–4416Exploring the minimal functional unit of the transporter
associated with antigen processing
Joachim Koch, Renate Guntrum, Robert Tampe´*
Institute of Biochemistry, Biocenter, Johann Wolfgang Goethe-University Frankfurt, Marie-Curie-Strasse 9, D-60439 Frankfurt a.M., Germany
Received 18 May 2005; revised 25 June 2005; accepted 11 July 2005
Available online 19 July 2005
Edited by Felix WielandAbstract TAP, an ABC transporter in the ER membrane, pro-
vides antigenic peptides derived from proteasomal degradation to
MHC class I molecules for inspection by cytotoxic T lympho-
cytes at the cell surface so as to trace malignant or infected cells.
To investigate the minimal number of transmembrane segments
(TMs) required for assembly of the TAP complex based on
hydrophobicity algorithms and alignments with other ABC
transporters we generated N-terminal truncation variants of hu-
man TAP1 and TAP2. As a result, a 6 + 6 TM core-TAP com-
plex represents the minimal functional unit of the transporter,
which is essential and suﬃcient for heterodimer assembly, pep-
tide binding, and peptide translocation into the ER. The TM1
of both, core-TAP1 and core-TAP2 are critical for heterodimer-
ization of the complex.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The survival of vertebrates eminently depends on the adap-
tive immune system to protect the organism against invaders
or cancer. For this purpose, the MHC class I-dependent
pathway of antigen processing can trigger elimination of af-
fected cells by cytotoxic T lymphocytes (CTL) upon presenta-
tion of antigenic peptides at the cell surface. The majority of
peptides are derived from proteasomal degradation [1] and,
after further trimming by TPPII [2], translocated into the
ER lumen via the transporter associated with antigen pro-
cessing (TAP) [3]. After loading MHC class I molecules with
high-aﬃnity peptides, peptide-MHC complexes are shuttled
to the plasma membrane for inspection by CTL [3–5]. In
the absence of a functional TAP transporter, most class I
molecules are not loaded with peptides and as a consequence
retained in the ER and ultimately directed to proteasomal
degradation [6–8]. An eﬃcient loading of high-aﬃnity pep-
tides onto class I molecules hence depends on the formationAbbreviations: ABC, ATP-binding cassette; CTL, cytotoxic T-lym-
phocyte; MHC, major histocompatibility complex; NBD, nucleotide-
binding domain; TAP, transporter associated with antigen processing;
TM, transmembrane segment; TMD, transmembrane domain
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doi:10.1016/j.febslet.2005.07.006of a macromolecular peptide-loading complex consisting of
TAP, MHC class I, tapasin, ERp57, and calreticulin [9,10].
TAP is a member of the family of ATP-binding cassette
(ABC) transporters and comprises a heterodimer of TAP1
(81 kDa) and TAP2 (76 kDa) (see Fig. 1A). Both subunits
are divided into a transmembrane domain (TMD) and a nucle-
otide-binding domain (NBD), which energizes peptide trans-
port by ATP hydrolysis [11]. We could show that the TMD
can be functionally separated into a core-complex of two times
six transmembrane segments (TM), which is suﬃcient for pep-
tide recognition and transport, and N-terminal domains essen-
tial for the assembly of the peptide-loading complex by
recruiting the adapter protein tapasin [12].
We determined in this study the minimal number of TMs
needed for the formation of a functional heterodimeric TAP
complex on the basis of N-terminal truncation studies. These
data are of particular interest in the light of other ABC trans-
porters (see Transporter Classiﬁcation Database, TCDB, at
http://tcdb.ucsd.edu/tcdb), which have less than two times six
TMs such as the Escherichia coli macrolide antibiotic exporter
MacB [13] and the lipoprotein exporter LolC/LolE [14], respec-
tively.2. Materials and methods
2.1. Cloning and expression of TAP constructs
To generate deletion mutants of human TAP1 (mini5TAP1, D2
–211) and TAP2 (mini5TAP2, D2–174), the primer pairs
5 0-CAGCTCGAGATGACTGACTGGATTCTACAAGATG-3 0, and
5 0-CTGCTCGAGTCATTCTGGAGCATCTGCAGGAGCC-3 0, and
5 0-CAGGCGGCCGCATGCGTGTGATTGACATCCTG-3 0, and 5 0-
CTGGCGGCCGCTCAGAGCTGGGCAAGCTTCTGC-3 0 were
used, respectively. Diﬀerent combinations of TAP1 and TAP2 (mini5-
TAP1/mini5TAP2, mini5TAP1/mini6TAP2, and mini6TAP1/mini5-
TAP2; the generation of mini6TAP was described previously [12])
were cloned into the expression vector pFASTBacDual (Invitrogen).
Recombinant baculoviruses were generated using the Bac-to-Bac
Baculovirus Expression system according to the manufacturers instruc-
tions (Invitrogen).
2.2. Cell culture and microsome preparation
Insect cells (Spodoptera frugiperda (Sf9)) were grown in Sf900II med-
ium (Invitrogen) following standard procedures. Infection with recom-
binant baculovirus and preparation of microsomes were performed as
described [15].
2.3. Peptide-transport assays
2.5 · 106 Sf9 cells were incubated with 0.01% of saponin in a total
volume of 50 ll AP-buﬀer (5 mM MgCl2 in PBS) for 1 min at 27 C.
Cells were washed twice with AP-buﬀer to remove the excess of deter-
gent. Transport was performed with 500 nM of ﬂuorescein-labeledblished by Elsevier B.V. All rights reserved.
Fig. 2. Peptide transport of truncated TAP variants in semi-perme-
abilized cells. Peptide translocation assays were performed with
ﬂuorescein-labeled peptide (500 nM; RRYQNSTCUL) in the presence
of MgATP (10 mM, black bars) or apyrase (1 U, open bars) for 3 min
at 32 C. Aliquots of the cells expressing TAP truncation variants
(5 · 105 cells/lane) were separated by SDS–PAGE and analyzed by
immunoblotting using mAbs 148.3 and 435.3 (ﬁgure inlet).
Fig. 1. Design and expression of truncated TAP variants. (A) Topolog-
ical model of human TAP based on hydrophobicity analysis and
sequence alignment with human MDR1. TMs of the N-terminal
domains are shown as open cylinders, those being part of the core-
domain of the complex as shaded cylinders [12]. The sites used to
generate diﬀerent deletionmutants of TAP1 andTAP2 are indicated. (B)
Microsomes (50 lg protein/lane) prepared frombaculovirus infected Sf9
cells were analyzedbySDS–PAGEand immunoblottingwith the human
TAP1- and TAP2-speciﬁc mAbs 148.3 and 435.3, respectively. Bound
antibodies were visualized by chemiluminiscence imaging.
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indicates ﬂuorescein coupled via a cysteine residue) in the presence of
10 mM ATP or 1 U of apyrase for 3 min at 32 C. Peptide transport
was stopped with 1 ml of AP-buﬀer supplemented with 10 mM EDTA.
After centrifugation at 1500 · g, membranes were solubilized in 1 ml of
lysis buﬀer (50 mM Tris/HCl, 150 mMNaCl, 5 mMKCl, 1 mM CaCl2,
1 mM MnCl2, 1% NP-40; pH 7.5) for 10 min at 27 C. Insoluble pro-
teins were removed by centrifugation at 20000 · g and glycosylated
peptides were bound to concanavalin A Sepharose overnight at 4 C.
After double washing of the beads with lysis buﬀer, bound peptides
were eluted with 200 mM of methyl-a-D-mannopyranoside in lysis buf-
fer for 30 min at 27 C and quantiﬁed in a 96-well plate reader (Fluoro-
star Galaxy, BMG Labtechnologies, Jena, Germany).
2.4. Peptide-binding assays
Microsomes (100 lg protein) were incubated with 2 lM of the ﬂuo-
rescein-labeled RRYUKSTEL peptide in the absence or presence of a
400-fold excess of non-labeled competitor peptide (RRYQKSTEL) in
100 ll of AP-buﬀer for 15 min on ice. After solubilization with 1% SDS
in PBS, membrane associated peptides were quantiﬁed in a 96-well
plate reader. Peptides speciﬁcally bound to TAP were determined as
the amount of labeled peptide, which was displaced from the pep-
tide-binding pocket.
2.5. Co-immunoprecipitation
Microsomes (750 lg protein) were solubilized in 1 ml of lysis buﬀer
(50 mM Tris/HCl, 150 mM NaCl, 5 mMMgCl2, 1% digitonin; pH 7.5)
for 60 min on ice. Insoluble proteins were removed by centrifugation
at 100000 · g for 45 min at 4 C. Solubilized TAP1 and TAP2 were
co-immunoprecipitated on magneto beads (Dynabeads M-280 sheep
anti-mouse IgG,Dynal Biotech), which were loaded with the TAP2-spe-
ciﬁcmousemonoclonal antibody 435.3 [15] prior to incubation with sol-
ubilized protein. After incubation for 2 h at 4 C, the beads were washed
three timeswith 1 ml ofwashingbuﬀer (50 mMTris/HCl, 150 mMNaCl,
2 mM EDTA, 0.01% digitonin; pH 7.5). Proteins associated with the
beads were eluted with 40 ll of SDS sample buﬀer containing 300 mM
DTT and subsequently analyzed by SDS–PAGE and immunoblotting
with the TAP1-speciﬁc rabbit antiserum 1p2. The polyclonal antibody
1p2 was raised against the peptide epitope ETEFFQQNQTGNIMSR
according to Nijenhuis and Ha¨mmerling [16].3. Results and discussion
The TMD of most ABC transporters comprises six trans-
membrane segments (TM); however, extra N-terminal exten-
sions have evolved, which are related to secondary functions.
As for TAP, the 6 + 6 TM core complex (annotation of helices
based on hydrophobicity algorithms and alignments with other
ABC transporters of subfamily B) is suﬃcient to allow for pep-
tide binding and transport, whereas the N-terminal domains
are important for assembly of the peptide-loading complex
via recruitment of the adapter protein tapasin [12]. A compar-
ison of diﬀerent structures of membrane transporters made it
evident that 7–10 TMs are required to form a transport path-
way [17]. Proteins with less TMs need oligomerization to pat-
tern a tunnel through the membrane. On the basis of these
observations, we investigated a further possible subdivision
of the core-domains of TAP1 and TAP2.
As truncation mutants of human TAP1 and TAP2 proved
useful to examine the structural organization of the peptide-
loading complex and the structure–function relationship of
the heterodimeric complex [12], several deletion mutants of
TAP1 and TAP2 with ﬁve or six remaining TMs were gener-
ated (mini5/5TAP (D2–211/D2–174), mini5/6TAP (D2–211/
D2–122), and mini6/5TAP (D2–166/D2–174)) (Fig. 1A). These
TAP variants were heterologously expressed in insect cells
(Sf9) from a single baculovirus encoding both TAP1 (p10 pro-
moter) and TAP2 (polyhedrin promoter) as shown by immu-
noblotting using human TAP1- or TAP2-speciﬁc mouse
monoclonal antibodies (Fig. 1B).
To elucidate whether peptide transport was preserved in
these truncated TAP complexes we analyzed TAP-speciﬁc pep-
tide transport in semi-permeabilized cells. Therefore, Sf9 cells
expressing various TAP constructs were permeabilized with
saponin and used in peptide translocation assays with a ﬂuo-
rescein-labeled peptide (RRYQNSTUL), containing an N-core
glycosylation site to monitor its translocation into the ER-lu-
men. Surprisingly, although nearly equal amounts of the
TAP constructs were expressed as shown by immunoblotting
with TAP1- and TAP2-speciﬁc monoclonal antibodies (inlet
Fig. 4. Heterodimerization of truncated TAP variants. Microsomes
(100 lg protein) were solubilized with 1% digitonin; TAP1 and TAP2
were co-immunoprecipitated on magneto beads with the TAP2-speciﬁc
mouse mAb 435.3. Proteins associated with the beads were eluted
and analyzed by SDS–PAGE and immunoblotting with the TAP1-
speciﬁc rabbit antiserum 1p2. S, solubilized fraction; IP, immune
precipitate; N, negative control using a myc-speciﬁc mAb for immune
precipitation.
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port when compared to wt TAP (Fig. 2). Similar results were
obtained using isolated microsomes and radiolabeled peptide
(RRYQNSTEL) in an experimental setup as described previ-
ously (data not shown; [12]). Note, mini6/6TAP shows the
same transport activity as wt TAP [12].
Since TAP-dependent peptide translocation into the ER is a
dynamic process, which requires multiple structural rearrange-
ments within the TMDs and the NBDs [3], we next analyzed
peptide binding of the TAP constructs, representing the initial
step in peptide transport. Isolated microsomes were incubated
with 2 lM of ﬂuorescein-labeled peptide (RRYUKSTEL;
KD = 93 ± 9 nM [18]) in saturation binding experiments. The
extent of TAP-speciﬁc peptide binding was determined as the
amount of ﬂuorescent peptide, which could be competed from
the binding pocket of the complex with an excess of non-la-
beled peptide (RRYQKSTEL; KD = 213 ± 21 nM [12]). Both,
mini5/6TAP and mini6/5TAP showed less than 20% of speciﬁc
peptide binding activity when compared to wt TAP (Fig. 3).
Mini6/6TAP has the same peptide binding aﬃnity as wt TAP
[12]. However, no binding above background was detected
for mini5/5TAP (Fig. 3). The peptide binding pocket is local-
ized in the cytosolic loops between TM4 and TM5 and a
stretch of 15 amino acids C-terminal of TM6 of the core do-
mains of TAP1 and TAP2 [16]. All of these regions are present
in the TAP constructs displayed in our study.
Both, TAP1 and TAP2 contribute to peptide binding [19],
indicating that heterodimerization is a prerequisite for peptide
binding. Therefore, impaired activity of the truncation variants
could be due to a deﬁciency in heterodimer formation. We
therefore performed co-immunoprecipitation experiments with
a TAP2-speciﬁc antibody. Surprisingly, mini5/6TAP and
mini6/5TAP formed heterodimers as shown by immunoblot-
ting with a TAP1-speciﬁc rabbit polyclonal antibody, whereas
mini5/5TAP did not (Fig. 4). Worth mentioning, an additional
non-identiﬁed band of about 72 kDa was detected in the deter-
gent-solubilized fraction of mini5/5TAP. Our data clearly dem-
onstrate that impaired peptide transport and peptide binding
of mini5/6TAP and mini6/5TAP are not caused by a loss ofFig. 3. Peptide binding of truncated TAP variants. Microsomes
(100 lg protein) were incubated with ﬂuorescein-labeled peptide
(2 lM; RRYCUKSTEL) in the absence (black bars) or presence (open
bars) of a 400-fold excess of non-labeled competitor peptide
(RRYQKSTEL) for 15 min at 4 C.the assembly of the heterodimeric complex but due to a distur-
bance of dynamic processes within the heterodimer.
On sequence level the TMs in the core-TAP complex align
well with MsbA and P-glycoprotein, of which the X-ray and
low resolution structure were solved, respectively [20,21].
Although it is a matter of debate whether the structure of
the MsbA homodimer does indeed reﬂect the native domain
interface, also because the dimer interface would be too small
to confer thermodynamic stability [20,22], the packing of the
TMs of the MsbA monomer is similar to that observed for
P-glycoprotein [20]. Here, we provide biochemical evidence
that for the core-TAP complex also the TM1 are needed to
form a stable heterodimer interface.
Taken together, our data point out that the core-TAP com-
plex is essential and suﬃcient for heterodimerization of the
TAP complex, peptide binding and transport with the TM1
of core-TAP1 and core-TAP2 being crucial for heterodimeriza-
tion. However, it remains unclear how these TMs contribute to
the formation of an active transport complex. In spite of the
existence of ABC transporters with less than 6 TMs, such as
the E. coli macrolide antibiotic exporter MacB [13] and the
lipoprotein exporter LolC/LolE [14], respectively, our data
moreover our data show clearly that a 6 + 6 TM core-domain
represents the minimal active transporter for human TAP.
Further structural characterization of the TMDs of the TAP
heterodimer and related ABC transporters, especially with re-
spect to the relative orientation of the TMs to one another at
the dimer interface, will be essential for the understanding of
how the substrate translocation pathway is formed.
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